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Cycloserine and threo-dihydrosphingosine inhibit TNF-a-induced
cytotoxicity: evidence for the importance of de novo ceramide
synthesis in TNF-a signaling
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Measuring the cell death induced by tumor necrosis factor (TNF-a) in L929 cells, we discovered for the first time that L-cycloserine, an
established inhibitor of serine palmitoyltransferase, as well as DL-threo-dihydrosphingosine (threo-DHS, threo-sphinganine) significantly
protected against TNF-a-induced cytotoxicity. Under the same conditions sphingosine and DL-erythro-dihydrosphingosine (erythro-DHS) did
not change TNF-a-induced cytotoxicity, thus underlining the specificity of threo-DHS. In serine-labeled cells, newly (de novo) synthetized
labeled ceramide was significantly diminished by threo-DHS alone or together with TNF-a, which makes the (dihydro) ceramide synthase
the likely target of threo-DHS. These results suggest the decisive role of ceramide de novo synthesis in TNF signaling.
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kine produced mainly by macrophages. It mediates inflam-
mation and regulates immune function by triggering the
synthesis and secretion of most, if not all, pro-inflammatory
mediators including IL-1, other cytokines, and lipid medi-
ators like platelet-activating factor [1,2]. Dysregulation of
TNF-a signaling results in a wide spectrum of human
diseases including sepsis, cancer, multiple sclerosis and
rheumatoid arthritis [3]. TNF-a is unique in its cytostatic
or cytotoxic effect on tumors, especially on tumor cells in
culture such as the murine fibrosarcoma cell line L929 [1,4].
The ligation of TNF-a to its receptor induces signal cas-
cades via adaptor proteins leading to a change in gene
expression connected to cell growth, differentiation or cell
death depending on the context [1,5,6]. Key enzymes
involved in TNF-a signaling are phospholipases, sphingo-
myelinases, protein kinases, protein phosphatases, pro-
teases, etc. Ceramide is considered to be a key player in
inducing cell death. In L929 cells there are contradictory
reports on ceramide augmentation by TNF-a via activation
of sphingomyelinases [1,7,8]. A role of de novo synthesis of0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.10.002
* Corresponding author. Tel.: +49-201-723-4104; fax: +49-201-723-
5943.
E-mail address: sybille.meyer@uni-essen.de (S.G.E. Meyer).ceramide was only shown in TNF/cycloheximide-induced
cell death in cerebral endothelial cells using Fumonisin B1
[9]. Some inducers of cell death other than TNF-a (inducers
like daunorubicin and other agents used in chemotherapy)
depend on de novo synthesis of ceramide [10]. Their
efficacy is enhanced by their combination with threo-DHS
(safingol), which was tested in a clinical study (phase I).
The assumed target of threo-DHS was thought to be PKC.
In this paper, we show that de novo synthesis of ceramide is
indispensable in TNF-a signaling in L929 cells by demon-
strating the protective effect of cycloserine on TNF-a. We
also report our discovery of the protective effect of threo-
dihydrosphingosine (threo-DHS) on TNF-a-induced cyto-
toxicity and identify the (dihydro)ceramide synthase as its
most likely target in TNF-a signaling in L929 cells by
taking advantage of the results of [11,12].
L929 cells were incubated in the presence or absence of
TNF-a for 24 h with cycloserine (10 mM), the well-
established suicide inhibitor of serine palmitoyltransferase
[13], on the one hand, and the closely related sphingolipids
DL-threo-dihydrosphingosine (threo-DHS), DL-erythro-dihy-
drosphingosine (erythro-DHS) and sphingosine (5 AM each)
on the other hand. Subsequently the viability of the cells
was determined. Fig. 1 shows that cyloserine and threo-
DHS decreased the TNF-a-induced cytotoxicity about 40%
Fig. 1. Effect of various sphingolipids and cycloserine on TNF-a-induced
cytotoxicity. Murine fibroblast cells L929 were grown in Minimum
essential medium Eagle (MEM, Sigma, Taufkirchen, Germany) in the
presence of 10% fetal calf serum, penicillin/streptomycin (105 U, 0.1 g/l
MEM, respectively, Sigma) and 2 mM glutamine (Serva, Heidelberg,
Germany) (supplemented MEM) at 37 jC in a humidified atmosphere of
5% CO2. 2 105 cells/ml were seeded in supplemented MEM in 24-well
microtiter plates (Falcon, Becton-Dickinson, Heidelberg, Germany), (0.4
ml/well). After 6 h, cells were washed twice with Hanks’ buffered salt
solution (HBSS) and re-fed with supplemented MEM as given above but
buffered with HEPES (25 mM) and incubated for 16–18 h. Subsequently,
cells were again washed twice with HBSS and incubated in serum- and
penicillin/streptomycin-free medium (0.4 ml/well) but with bovine serum
albumin fraction V (Serva), (4%, w/v), glutamine (2 mM) and effectors.
Control: absence of effectors or presence of effectors: TNF-a (Boehringer
Ingelheim, Heidelberg, Germany, 20 ng/ml) or threo-DHS, erythro-DHS or
sphingosine (all three from Sigma; 5 AM, dissolved in dimethyl sulfoxide/
ethanol, 1:1, v/v; final solvent concentrations 0.2% each), and L-cycloserine
(also from Sigma, see above, 10 mM, dissolved in HBSS) together with
TNF-a. Viability of the cells was assessed after 24 h of incubation by the
release of cytosolic lactate dehydrogenase (LDH) [15]. Cytotoxicity
induced by TNF-a alone was set 100%. n= 4, meanF S.D. Different
letters indicate that these groups are significantly different, a= 0.05 (by
Duncan’s multiple range test).
Fig. 2. Effect of TNF-a, threo-DHS or both on newly synthetized labeled
ceramide. Incubation of the cells, extraction and quantification of lipids
were done as reported in Ref. [14]: Cells (2.2 ml, 2 105 cells/ml) were
seeded in supplemented MEM in six-well microtiter plates on coverslips
(F 32 mm, from Bachofer Reutlingen, Germany). After 6 h, cells were
washed and re-fed with unlabeled serine-free supplemented MEM buffered
with HEPES and L-[3-3H]serine (Amersham Pharmacia Biotech, Freiburg,
Germany), (59.2 kBq, 28 nM) for 16–18 h (long-term labeling).
Subsequently, cells were washed and incubated in 0.8-ml unlabeled serine-
and serum-free medium but with L-[U-14C]serine (Amersham Pharmacia
Biotech) (31.7 kBq, 7 AM), albumin (4%, w/v) and glutamine (2 mM) for
another 30 min (short-term labeling) in the absence of effectors (control)
and in the presence of threo-DHS (5 AM, dissolved in dimethyl sulfoxide
(1:1, v/v; final solvent concentrations 0.2%) or threo-DHS together with
TNF-a (20 ng/ml). After this incubation, the lipids of the cells were
extracted as described in Ref. [16]. The incorporated radiolabel of ceramide
present in the organic phase was determined by separating the lipids by
thin-layer chromatography (chloroform/methanol/water/glacial acetic acid,
90:75:6:1.5; v/v/v/v) [17]. By this method [14C]ceramide is surely separated
from other labeled sphingolipids like sphingomyelin and sphingosine and
labeled glycerophospholipids like phosphatidylserine and phosphatidyle-
thanolamine (for verification of the ceramide spot in this system see our
own publication [14]). References were visualized with iodine vapor. In
accordance with the autoradiogram, the radioactive spots were scraped off
and the radioactivity counted in a liquid scintillation counter (Beckman
Coulter, Unterschleißheim, Germany). 14C-radioactivity represents the
radioactivity only measured in the 14C-window (397–655) of the counter,
excluding the radioactivity measured in the overlapping 3H- and 14C-
window (0–397). Total radioactivity was measured in the window (0–
655). Only the results of 14C-label, measured in the non-overlapping 14C-
window (397–655) of the liquid scintillation counter, are shown. In the
control the relative contribution of ceramide to the total 14C-radioactivity
of the lane was 12.0%. Total 14C-radioactivity per lane (cpm): control:
522F 124, TNF-a: 496F 53, threo-DHS: 628F 184 and TNF-a and
threo-DHS: 661F159. The data are shown as % of control. Different
letters indicate that these groups are significantly different, a= 0.05. n= 3,
meansF S.D. (by Duncan’s multiple range test).
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pids erythro-DHS and sphingosine had no effect. In the
absence of TNF-a, no effector showed relevant cytotoxicity
by itself (not shown). It has been reported by us before [14]
that cycloserine inhibited [14C]ceramide synthesis in
Fig. 3. TNF-a-induced cell death depends on ceramide de novo synthesis.
By the ligation of TNF-a to its receptor, de novo synthesis of ceramide is
switched on by an unknown mechanism (see horizontal arrow). The first
enzyme of ceramide de novo synthesis (serine palmitoyltransferase) is
inhibited by cycloserine [13]. Threo-dihydrosphingosine is an inhibitor and
a substrate (analog to the natural substrate erythro-DHS) of dihydrocer-
amide synthase [11,12]. Cycloserine as well as threo-DHS decrease both
TNF-a-induced cytotoxicity and ceramide synthesis. The pathway from
ceramide to cell death is not fully understood.
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of incubation. The same is true for incubation of L929 cells
with cycloserine together with TNF-a (Meyer and de Groot,
unpublished). The question arises if threo-DHS, which is an
analog to the natural substrate D-erythro-DHS of the (dihy-
dro)ceramide synthase, also diminishes ceramide synthesis.
Furthermore, it has been documented recently that threo-
DHS is a substrate as well as an inhibitor of the (dihydro)-
ceramide synthase [11,12]. The possible change in ceramide
concentration induced by threo-DHS and TNF-a was
checked by labeling L929 cells at first with [3H]serine for
16–18 h and afterwards by labeling the same cells with
[14C]serine for 30 min in the absence (control) and presence
of TNF-a, threo-DHS or threo-DHS together with TNF-a.This method makes it possible to differentiate between a
total labeled (within 16–18 h) ceramide pool ([3H +
14C]serine-labeled ceramide), and the newly (within 30
min) synthetized ceramide pool ([14C]ceramide). In com-
parison with control incubations, TNF-a increased the
[3H + 14C]serine-labeled ceramide by less than 5%, threo-
DHS and threo-DHS together with TNF-a reduced
[3H + 14C]serine-labeled ceramide by about 5% and 10%,
respectively (not shown). These changes were not signif-
icant. Fig. 2 shows only the newly synthetized [14C]serine-
labeled ceramide. TNF-a alone did not change [14C]ceram-
ide in comparison with the control incubation (about 100%
of control) but threo-DHS alone as well as together with
TNF-a reduced newly synthetized [14C]ceramide on the
same extent by about 20% significantly. The discovery of
the significant reduction of ceramide by threo-DHS was
only possible by separating the newly synthetized ceramide
pool from the total ceramide pool. In short, these results
suggest the assumption that de novo ceramide synthesis
has a decisive influence on TNF-a signaling and make
(dihydro) ceramide synthase the likely target of threo-DHS
(Fig. 3).Acknowledgements
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